GEZLID-30

Description

GEZLID-30 contains Gliclazide 30 mg in a modified-release tablet formulation. Gliclazide belongs to the sulfonylurea class of oral antidiabetic medicines and helps lower blood glucose by stimulating the pancreas to release insulin. It may be prescribed for adults with type 2 diabetes mellitus when appropriate alongside dietary measures, physical activity and regular diabetes monitoring.

For related diabetic and cardiovascular formulations, explore the Cardries Biotic range from Medhexa Pharma for pharmaceutical products and business enquiries.

Therapeutic Segment

Anti-Diabetic Therapy | Type 2 Diabetes Management | Sulfonylureas | Modified Release Tablets | Blood Glucose Control

Uses of GEZLID-30

GEZLID-30 may be prescribed as part of an individualized treatment plan for:

• Type 2 diabetes mellitus
• Inadequate blood glucose control with diet and exercise alone
• Patients requiring sulfonylurea therapy
• Improving glycaemic control when additional oral antidiabetic treatment is required
• Long-term blood glucose management under medical supervision

Gliclazide is intended for type 2 diabetes and should be used together with appropriate dietary measures and physical activity.

It is not indicated for the treatment of type 1 diabetes mellitus or diabetic ketoacidosis.

Key Benefits of GEZLID-30

• Blood Glucose Control: Helps reduce elevated blood glucose levels in adults with type 2 diabetes.
• Sulfonylurea Action: Stimulates pancreatic beta cells to release insulin.
• Modified Release Formulation: Provides gradual release of gliclazide according to the characteristics of the formulation.
• 30 mg Strength: Contains Gliclazide 30 mg in a convenient oral tablet.
• Supports Long-Term Diabetes Management: May form part of an individualized treatment plan when lifestyle measures alone do not provide adequate glucose control.
• Convenient Oral Formulation: Designed for administration according to the prescribed dosing schedule.

How GEZLID-30 Works

Gliclazide belongs to the sulfonylurea group of oral antidiabetic medicines.

It acts primarily on pancreatic beta cells by binding to specific sulfonylurea receptors. This stimulates insulin secretion and helps lower blood glucose levels.

The modified-release formulation provides a controlled release of gliclazide over time. This can support blood glucose management with a convenient dosing schedule when used according to the approved product instructions.

Because gliclazide stimulates insulin release, its glucose-lowering effect can continue even when blood glucose is not significantly elevated. Therefore, hypoglycaemia remains an important potential adverse effect, particularly when meals are skipped, the dose is inappropriate or other glucose-lowering medicines are used at the same time.

Common Side Effects of GEZLID-30

Some people may experience side effects while taking gliclazide. Possible effects include:

• Hypoglycaemia
• Nausea
• Indigestion
• Abdominal discomfort
• Diarrhoea or constipation
• Headache
• Dizziness
• Increased appetite
• Weight gain
• Skin rash

Hypoglycaemia can cause sweating, shaking, hunger, dizziness, weakness, confusion, difficulty concentrating or a rapid heartbeat.

Seek urgent medical attention if symptoms of severe hypoglycaemia occur or if the person becomes unconscious.

Important Safety Information

Use GEZLID-30 only according to the advice of a qualified healthcare professional.

• Take gliclazide regularly and follow the prescribed meal and dosing schedule. Skipping meals can increase the risk of hypoglycaemia.
• Learn to recognize symptoms of low blood sugar, especially if GEZLID-30 is combined with insulin or other medicines that can cause hypoglycaemia.
• Do not take an additional tablet to compensate for a missed dose unless specifically instructed by your healthcare professional.
• Tell your doctor if you have kidney or liver disease, as these conditions can affect the safety and management of glucose-lowering treatment.
• Inform your healthcare professional if you have a history of severe or recurrent hypoglycaemia.
• Alcohol can increase the risk of hypoglycaemia and may affect blood glucose control. Discuss alcohol use with your healthcare professional.
• Tell your doctor about all medicines you take, including other antidiabetic medicines, antibiotics, anticoagulants and over-the-counter products, because some medicines can alter blood glucose or gliclazide effects.
• Monitor blood glucose as recommended by your diabetes-care team.
• Discuss pregnancy and breastfeeding with your healthcare professional before using gliclazide.
• Do not change the dose or stop treatment without medical advice.
• Modified-release tablets should generally be swallowed whole. Do not crush, chew or break the tablet unless the specific product information states that this is permitted.
• Seek medical attention for severe allergic reactions, persistent vomiting, significant weakness or other concerning symptoms.

For additional information about gliclazide, refer to the NHS guidance on gliclazide.

Dosage & Administration

Take GEZLID-30 exactly as prescribed by your healthcare professional.

For 30 mg modified-release gliclazide formulations, treatment commonly starts at 30 mg once daily, usually taken with breakfast. Depending on blood glucose response and tolerability, the healthcare professional may adjust the dose according to the approved product information.

The tablet should generally be swallowed whole with water and should not be crushed or chewed because it is a modified-release formulation.

Take the medicine at the same time each day and maintain regular meals. If you miss a dose, follow your healthcare professional’s instructions rather than taking an extra tablet.

The appropriate dose depends on blood glucose levels, age, kidney and liver function, other medicines and the patient’s overall response to treatment.

Storage

• Store in a cool, dry place.
• Protect the tablets from excessive heat and moisture.
• Keep the tablets in their original BLISTER packaging until use.
• Protect from direct sunlight.
• Keep out of the sight and reach of children.
• Do not use the product after the expiry date printed on the pack.